Scientists have created the elixir of youth

Scientists from the University of Leicester have come to the
conclusion that a targeted approach will solve the problem
of aging. That is, a drug that will "target" and act selectively
only on cells damaged by old age. For the error-free
identification of such (synescent) cells, a marker (target) is
needed, that is, a feature that distinguishes them from young
healthy cells. Using mass spectrometry, the scientists were
able to identify a number of markers that are formed in the
plasma membranes of senescent cells. As a result, it was
decided to use the B2M extracellular epitope, which is part
of the antigen molecule, as a marker for the drug.
To recognize the marker, the researchers decided to use
monoclonal antibodies. They can be developed against almost
any natural antigen. On their basis, scientists have created an
antibody-drug conjugate (ADC). The principle of the drug is
based on the use of monoclonal antibodies with a biologically
active cytotoxic drug. ADCs first bind to an antigen located
on the cell surface, after which a toxic drug enters the cell.
Thus, the ADC acts like a "smart bomb" - it finds the "target"
and hits it.
The drug for the rejuvenation of the body has shown its
effectiveness in cell cultures under laboratory conditions. The
results were promising. The drug was really good at recognizing
senescent cells and destroying them with toxins. At the same
time, it turned out to be safe for young, healthy cells. This speaks
of the safety of the treatment. Details are published in the journal
Nature (https://go.nature.com/3njuEoL).